• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

    3/10/23 11:42:36 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email
    SC 13G/A 1 tm239149d1_sc13g.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C.  20549

     

     

     

    SCHEDULE 13G 

    (Amendment no. 5)

     

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments 

    Thereto Filed Pursuant to § 240.13d-2.

     

    Under the Securities Exchange Act of 1934

     

    Allarity Therapeutics, Inc. 

    (Name of Issuer)

     

                  COMMON STOCK, PAR VALUE $0.0001PER SHARE              

    (Title of Class of Securities)

     

              016744104         

    (CUSIP Number)

     

                            March 2, 2023                      

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b) 

    ¨  Rule 13d-1(c) 

    ¨  Rule 13d-1(d)

     

     

     

     

     

    Page 1 of 6 Pages

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 2 of 6 Pages

             
    1)

    NAME OF REPORTING PERSON

     

    Forsakringsaktiebolaget Avanza Pension

     

    2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       o

    (b)       o  

    3)

    SEC USE ONLY

     

     

    4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Stockholm, Sweden

     

    NUMBER

    OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5)

    SOLE VOTING POWER

     

    1,367,568

    6)

    SHARED VOTING POWER

     

     

    7)

    SOLE DISPOSITIVE POWER

     

     

    8)

    SHARED DISPOSITIVE POWER

     

    1,367,568

    9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,367,568

    10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

    11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4,56 %

    12)

    TYPE OF REPORTING PERSON

     

    FI

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 3 of 6 Pages

     

    Item 1(a). Name of Issuer:

     

    Allarity Therapeutics, Inc

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    24 School, St, 2Nd Floor

    BOSTON, MA, 02108

    United States

     

    Item 2(a).Name of Person Filing:

     

    Forsakringsaktiebolaget Avanza Pension

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    Box 13129

    Stockholm, Sweden 10303

     

    Item 2(c). Citizenship:

     

    Forsakringsaktiebolaget Avanza Pension is a company organized under the laws of Sweden

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, Par Value $0.0001 per share

     

    Item 2(e). CUSIP Number:  016744104

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)

     

      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)

     

      (c) ¨ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)

     

      (d) ¨ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

     

      (e) ¨ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)

     

      (f) ¨ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)

     

      (g) ¨ Parent Holding Company or control person in accordance with §240.13d-1(b)(1)(ii)(G)

      

      (h) ¨ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

     

      (i) ¨ Church plan that is excluded from the definition of an investment company under §3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 4 of 6 Pages

     

      (j) x A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)
           
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K)

     

    Item 4.

    Ownership.

    (This 13G is based on 30,000,000 shares of Common Stock outstanding)

     

      (a) Amount beneficially owned:  1,367,568

     

      (b)

    Percent of class: 4,56 %

     

     

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:  1,367,568

     

      (ii) Shared power to vote or to direct the vote:  None

     

      (iii) Sole power to dispose or to direct the disposition of:  None

     

      (iv) Shared power to dispose or to direct the disposition of: 1,367,568

     

      Number and Percentage
    of Shares Beneficially Owned
    Date
      4,56 % / 1,367,568 March 2, 2023

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 5 of 6 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

     

     

    CUSIP No.: 016744104 SCHEDULE 13G Page 6 of 6 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a Swedish insurance company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

    SIGNATURE

     

    After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    March 10, 2023  
       
       
    Marie Andersson / Middle Office  
    Name/Title  

     

     

    Get the next $ALLR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR

    DatePrice TargetRatingAnalyst
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

             TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP® algorithms in breast cancer, alongside laboratory services from Allarity's Medical Laboratory in Denmark. Under the agreement, Allarity will supply advanced transcriptome analysis services to support the part

    7/15/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    SEC Filings

    View All

    SEC Form 10-Q filed by Allarity Therapeutics Inc.

    10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)

    8/15/25 4:30:58 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Allarity Therapeutics Inc.

    NT 10-Q - Allarity Therapeutics, Inc. (0001860657) (Filer)

    8/14/25 4:05:13 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    7/16/25 7:20:57 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ervin Jeffrey S

    3 - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    7/14/25 11:51:07 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

    4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    1/24/25 8:10:53 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Director Benjamin Laura

    4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    1/24/25 8:09:04 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

    SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

    11/13/24 9:24:34 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Allarity Therapeutics Inc.

    SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)

    8/29/24 3:57:47 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

    SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

    2/12/24 9:52:15 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Leadership Updates

    Live Leadership Updates

    View All

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Announces Changes to Board of Directors

        TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acqua

    6/11/25 4:05:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

      Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio

    11/14/24 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

    - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s

    5/14/24 4:01:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Reports Third Quarter 2022 Financial Results

    Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:

    11/15/22 4:01:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care